{"access":{"can_view":true,"can_edit":false,"can_remove":false,"can_add":false,"can_publish":false,"can_get_doi":false,"can_share":true,"can_move":true,"can_move_outside":true,"can_transfer":true,"can_download":true,"limited_run":false,"limited_private_links":false,"limited_blind_links":false,"is_locked":false},"authors":[{"name":"Jorge        Machado Alba","affiliation":"Universidad Tecnológica de Pereira","affiliation_url":null,"username":"jorge--------machado-alba","link":null,"image":{"source":"/img/avatars/016.png","placeholder":"/img/avatars/016.png","webp_source":""},"note":"","is_verified_user":true,"orcid":"0000-0002-8455-0936"}],"before_start":"","book_chapter":null,"can_accept_authorship":false,"can_be_copied":true,"can_claim_authorship":false,"can_manage_keywords":true,"can_remove_fork":false,"can_sign":false,"child_steps":{},"cited_protocols":[],"collection_items":[],"created_on":1664231687,"creator":{"name":"Jorge        Machado Alba","affiliation":"","affiliation_url":null,"username":"jorge--------machado-alba","link":null,"image":{"source":"/img/avatars/016.png","placeholder":"/img/avatars/016.png","webp_source":""},"badges":[{"id":4,"name":"Gold power author!","image":{"source":"/img/badges/gold.svg","placeholder":"/img/badges/gold.svg"}}],"affiliations":[]},"description":"{\"blocks\":[{\"key\":\"6s4ud\",\"text\":\"Purpose: The aim was to analyze the characteristics, treatment patterns, persistence, and clinical outcomes of Colombian patients with Non-Valvular Atrial Fibrillation (NVAF) under treatment with oral anticoagulants (OAs).\",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[{\"style\":\"bold\",\"offset\":0,\"length\":9}],\"entityRanges\":[],\"data\":{}},{\"key\":\"a8hso\",\"text\":\"Patients and methods: Retrospective cohort in patients with NVAF, aged ≥18 years and of any sex, the first prescription of an OA (index) between January/2013 and June/2018, with a follow-up until June/2019. Data from the clinical history, patient characteristics, pharmacological variables, treatment switch, cerebrovascular events and safety were searched. Descriptive analyzes were carried out.\",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[{\"style\":\"bold\",\"offset\":0,\"length\":22}],\"entityRanges\":[],\"data\":{}},{\"key\":\"e002m\",\"text\":\"Results: A total of 2076 patients with NVAF were included. The 57.0% of patients were women and the mean age was 73.3±10.4 years. Patients were followed for a mean of 2.3±1.6 years. 8.7% received warfarin before the index date. The most frequent OA was rivaroxaban (n=950; 45.8%), followed by warfarin (n=459; 22.1%) and apixaban (n=405; 19.5%). Hypertension was present in 87.5%, diabetes mellitus in 22.6% and severe renal failure in 5.2%. The mean CHA₂DS₂-VASc Score was 3.6±1.5. The main efficacy and safety outcomes were stroke (3.1%) and gastrointestinal bleeding (2.0%) respectively. From these, most events were in patients using warfarin at index (3.5% for stroke and 4.1% for gastrointestinal bleeding). The 18.0% of patients switched index OA during follow-up, while 11.7% discontinued the treatment. \",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[{\"style\":\"bold\",\"offset\":0,\"length\":9}],\"entityRanges\":[],\"data\":{}},{\"key\":\"2er8i\",\"text\":\"Conclusion: The patients with NVAF in this study were mainly older adults with multiple comorbidities and high CHA₂DS₂-VASc score. The frequency of clinical events was similar to other observational studies, with low percentage of discontinuation.\",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[{\"style\":\"bold\",\"offset\":0,\"length\":12}],\"entityRanges\":[],\"data\":{}}],\"entityMap\":{}}","disclaimer":"","document":"","documents":[{"id":0,"type_id":0,"filename":"","key":"","color":"","height":0,"width":0,"is_document":null,"original_file_id":null,"thumb_url":"https://www.protocols.io/img/extensions/xlsx.png","size":null,"is_private":0,"is_new":0,"ofn":"DB Anticoagulants.xlsx","url":"https://content.protocols.io/files/jb5ubamqp.xlsx","bucket_name":null,"s3_webp_url":"","file_id":296818}],"doi":"dx.doi.org/10.17504/protocols.io.rm7vzb852vx1/v1","doi_status":1,"ethics_statement":null,"fork_id":null,"fork_info":null,"forks":[],"funders":[{"funder_name":"Pfizer","grant_id":"B1801420"}],"groups":[],"guid":"3B16C3F03DEB11EDADEBD192C55098D4","guidelines":"","has_references":false,"has_step_reagents":false,"has_versions":false,"id":70526,"image":{"source":"https://www.protocols.io/img/default_protocol.png","webp_source":null,"placeholder":"https://www.protocols.io/img/default_protocol.png","webp_placeholder":null},"image_attribution":"","in_trash":false,"is_bookmarked":false,"is_contact_suspended":false,"is_content_confidential":false,"is_content_warning":false,"is_doi_reserved":true,"is_in_pending_publishing":false,"is_in_transfer":false,"is_owner":true,"is_research":true,"is_retracted":false,"is_shared_directly":false,"is_subprotocol":null,"is_unlisted":false,"item_id":1015842,"journal":null,"journals":[{"journal_id":"10.2147/VHRM.S391549","name":"Vascular Health and Risk Management","group_id":1,"link":"https://doi.org/10.2147/VHRM.S391549","citation":"Machado-Duque ME,  Gaviria-Mendoza A,  Reyes JM,  Mesa A,  Castaño-Gamboa N,  Valladales-Restrepo LF,  Machado-Alba JE, Clinical Characteristics, Patterns of Use, and incidence of Adverse Events in Patients With Nonvalvular Atrial Fibrillation Treated With Oral Anticoagulants in Colombia. Vascular Health and Risk Management  doi: \u003ca target=\"_blank\" href=\"https://dx.doi.org/10.2147/VHRM.S391549\"\u003e10.2147/VHRM.S391549\u003c/a\u003e ","is_main":false}],"keywords":"Anticoagulation; Direct Oral Anticoagulant; Non-valvular Atrial Fibrillation; Warfarin; Real-world study; Pharmacoepidemiology","last_modified":1680908287,"link":"https://doi.org/10.2147/VHRM.S391549","location":null,"manuscript_citation":"Machado-Duque ME,  Gaviria-Mendoza A,  Reyes JM,  Mesa A,  Castaño-Gamboa N,  Valladales-Restrepo LF,  Machado-Alba JE, Clinical Characteristics, Patterns of Use, and incidence of Adverse Events in Patients With Nonvalvular Atrial Fibrillation Treated With Oral Anticoagulants in Colombia. Vascular Health and Risk Management  doi: \u003ca target=\"_blank\" href=\"https://dx.doi.org/10.2147/VHRM.S391549\"\u003e10.2147/VHRM.S391549\u003c/a\u003e ","materials":[],"materials_text":"","ownership_history":null,"parent_collections":[],"parent_protocols":[],"peer_reviewed":false,"protocol_references":"","public":true,"public_fork_note":"","published_on":1680908287,"references":[],"related_equipments":[],"related_materials":[],"reserved_doi":"10.17504/protocols.io.rm7vzb852vx1/v1","retraction_reason":null,"samples":{},"shared_access_id":16,"show_comparison":false,"sign_info":null,"state_version_id":8,"stats":{"is_voted":false,"number_of_views":2,"number_of_steps":0,"number_of_bookmarks":0,"number_of_comments":0,"number_of_bookmarked_comments":0,"number_of_steps_comments":0,"number_of_protocol_comments":0,"number_of_exports":0,"number_of_runs":0,"number_of_votes":0,"number_of_reagents":0,"number_of_equipments":0,"number_of_collections":0,"number_of_forks":{"private":0,"public":0},"number_of_accessible_forks":0},"status":{"id":1,"info":"We use this protocol and it's working"},"steps":null,"template_id":1,"title":"CLINICAL CHARACTERISTICS, PATTERNS OF USE, AND INCIDENCE OF ADVERSE EVENTS IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION TREATED WITH ORAL ANTICOAGULANTS","title_html":"CLINICAL CHARACTERISTICS, PATTERNS OF USE, AND INCIDENCE OF ADVERSE EVENTS IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION TREATED WITH ORAL ANTICOAGULANTS","type_id":1,"units":[{"id":1,"type_id":3,"name":"µL","can_manage":0,"read_only":0},{"id":2,"type_id":3,"name":"mL","can_manage":0,"read_only":0},{"id":3,"type_id":3,"name":"L","can_manage":0,"read_only":0},{"id":4,"type_id":3,"name":"µg","can_manage":0,"read_only":0},{"id":5,"type_id":3,"name":"mg","can_manage":0,"read_only":0},{"id":6,"type_id":3,"name":"g","can_manage":0,"read_only":0},{"id":7,"type_id":3,"name":"kg","can_manage":0,"read_only":0},{"id":8,"type_id":3,"name":"ng","can_manage":0,"read_only":0},{"id":9,"type_id":3,"name":"Hz","can_manage":0,"read_only":0},{"id":10,"type_id":24,"name":"°C","can_manage":0,"read_only":0},{"id":11,"type_id":24,"name":"°К","can_manage":0,"read_only":0},{"id":12,"type_id":24,"name":"°F","can_manage":0,"read_only":0},{"id":13,"type_id":25,"name":"Mass Percent","can_manage":0,"read_only":0},{"id":14,"type_id":25,"name":"% volume","can_manage":0,"read_only":0},{"id":15,"type_id":25,"name":"Mass / % volume","can_manage":0,"read_only":0},{"id":16,"type_id":25,"name":"Parts per Million (PPM)","can_manage":0,"read_only":0},{"id":17,"type_id":25,"name":"Parts per Billion (PPB)","can_manage":0,"read_only":0},{"id":18,"type_id":25,"name":"Parts per Trillion (PPT)","can_manage":0,"read_only":0},{"id":19,"type_id":25,"name":"Mole Fraction","can_manage":0,"read_only":0},{"id":20,"type_id":25,"name":"Mole Percent","can_manage":0,"read_only":0},{"id":21,"type_id":25,"name":"Molarity (M)","can_manage":0,"read_only":1},{"id":22,"type_id":25,"name":"Molarity (m)","can_manage":0,"read_only":0},{"id":23,"type_id":25,"name":"Genome copies per ml","can_manage":0,"read_only":0},{"id":24,"type_id":3,"name":"μV","can_manage":0,"read_only":0},{"id":25,"type_id":3,"name":"ms","can_manage":0,"read_only":0},{"id":26,"type_id":3,"name":"pg","can_manage":0,"read_only":0},{"id":27,"type_id":25,"name":"Molarity dilutions","can_manage":0,"read_only":0},{"id":28,"type_id":25,"name":"millimolar (mM)","can_manage":0,"read_only":0},{"id":29,"type_id":25,"name":"micromolar (µM)","can_manage":0,"read_only":0},{"id":30,"type_id":25,"name":"nanomolar (nM)","can_manage":0,"read_only":0},{"id":31,"type_id":25,"name":"picomolar (pM)","can_manage":0,"read_only":0},{"id":32,"type_id":24,"name":"Room temperature","can_manage":0,"read_only":0},{"id":33,"type_id":30,"name":"rpm","can_manage":0,"read_only":0},{"id":34,"type_id":30,"name":"x g","can_manage":0,"read_only":0},{"id":165,"type_id":24,"name":"On ice","can_manage":0,"read_only":0},{"id":200,"type_id":32,"name":"cm","can_manage":0,"read_only":0},{"id":201,"type_id":32,"name":"mm","can_manage":0,"read_only":0},{"id":202,"type_id":32,"name":"µm","can_manage":0,"read_only":0},{"id":203,"type_id":32,"name":"nm","can_manage":0,"read_only":0},{"id":204,"type_id":25,"name":"mg/mL","can_manage":0,"read_only":0},{"id":205,"type_id":25,"name":"µg/µL","can_manage":0,"read_only":0},{"id":206,"type_id":25,"name":"% (v/v)","can_manage":0,"read_only":0},{"id":1324,"type_id":30,"name":"rcf","can_manage":0,"read_only":0},{"id":1359,"type_id":35,"name":"Bar","can_manage":0,"read_only":0},{"id":1360,"type_id":35,"name":"Pa","can_manage":0,"read_only":0}],"uri":"clinical-characteristics-patterns-of-use-and-incid-cg46tyze","url":"https://www.protocols.io/view/clinical-characteristics-patterns-of-use-and-incid-cg46tyze","version_class":70526,"version_data":{"id":0,"code":"cg46tyze","version_class":70526,"parent_id":null,"parent_uri":null,"is_same_owner":false,"is_parent_public":false,"has_pending_merge_request":false,"has_approved_merge_request":false,"merge_request":null},"version_id":0,"version_uri":"clinical-characteristics-patterns-of-use-and-incid-rm7vzb852vx1/v1","versions":[{"id":70526,"title":"CLINICAL CHARACTERISTICS, PATTERNS OF USE, AND INCIDENCE OF ADVERSE EVENTS IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION TREATED WITH ORAL ANTICOAGULANTS","title_html":"CLINICAL CHARACTERISTICS, PATTERNS OF USE, AND INCIDENCE OF ADVERSE EVENTS IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION TREATED WITH ORAL ANTICOAGULANTS","image":{"source":"https://www.protocols.io/img/default_protocol.png","webp_source":null,"placeholder":"https://www.protocols.io/img/default_protocol.png","webp_placeholder":null},"doi":"dx.doi.org/10.17504/protocols.io.rm7vzb852vx1/v1","uri":"clinical-characteristics-patterns-of-use-and-incid-cg46tyze","published_on":1680908287,"modified_on":1680908287,"version_class":70526,"version_id":0,"version_code":"cg46tyze","version_uri":"clinical-characteristics-patterns-of-use-and-incid-rm7vzb852vx1/v1","created_on":1664231687,"categories":null,"creator":{"name":"Jorge        Machado Alba","affiliation":null,"affiliation_url":null,"username":"jorge--------machado-alba","link":null,"image":{"source":"/img/avatars/016.png","placeholder":"/img/avatars/016.png","webp_source":""}},"stats":{"number_of_comments":0,"last_comment_time":0}}],"warning":""}